Truxima Hits 20% Share For Teva
Rheumatoid Arthritis Indication Helps Rituximab Biosimilar Gain Ground In US
Executive Summary
Teva says the Truxima rituximab biosimilar it sells in the US in partnership with Celltrion has captured a fifth of the market a year after launch, driven in part by its exclusive rheumatoid arthritis indication.